RESET-PKD:短期生酮干预治疗常染色体显性多囊肾病的先导试验
RESET-PKD 为单臂先导试验,纳入 10 例快速进展的常染色体显性多囊肾病(ADPKD)患者,先维持高碳水饮食,再进入 3 天禁水(WF)或 14 天生酮饮食(KD)两组。短期生酮干预有效诱导酮体生成且在日常中可行,总肾脏体积未变,总肝脏体积在生酮开始后显著下降(V2 至 V3:-7.7%,P = .01),作者认为肾脏体积变化可能需要更长期干预。
要点
- 10 例快速进展 ADPKD 患者中 9/10 达到生酮状态,9/10 评价短期生酮干预可行。
- 总肾脏体积(TKV)在试验期间未发生变化。
- 总肝脏体积在生酮开始后显著下降(V2 至 V3:-7.7%,P = .01),由非囊性部分变化介导。
核心结论
- RESET-PKD 表明短期生酮干预可有效诱导生酮,且对 ADPKD 患者在日常生活中可行;总肝脏体积在生酮开始后迅速变化,而总肾脏体积变化可能需要更长期干预。
研究设计与样本
- 先导试验,10 例快速进展的常染色体显性多囊肾病(ADPKD)患者,V1 时先维持高碳水饮食,V2 时进入 3 天禁水(WF,n=5)或 14 天生酮饮食(KD,n=5)两组,V3 后恢复常规饮食 3-6 周至 V4。
- 每次访视行肾脏与肝脏磁共振体积测量,评估酮体以判断代谢效果,并用问卷确定可行性。
主要发现
- 所有参与者(KD 组 n=5,WF 组 n=5)年龄 39.8 ± 11.6 岁,估算肾小球滤过率 82 ± 23.5 mL/min/1.73 m2,总肾脏体积 2224 ± 1156 mL,均属 Mayo 1C-1E 类。
- 两个研究组的呼气丙酮与血 β-羟丁酸(BHB)水平均升高(V1 至 V2 平均丙酮:2.7 ± 1.2 p.p.m.,V2 至 V3:22.8 ± 11.9 p.p.m.,P = .0006;V1 至 V2 平均 BHB:0.22 ± 0.08 mmol/L,V2 至 V3:1.88 ± 0.93 mmol/L,P = .0008)。
- 10 例患者中 9 例达到生酮状态,9/10 评价生酮饮食干预可行。
- 试验期间总肾脏体积(TKV)未发生变化。
- 总肝脏体积(ΔTLV V2 至 V3:-7.7%,P = .01)显著下降,由非囊性部分变化介导。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ketogenic dietary interventions (KDI) have been shown to be effective in animal models of polycystic kidney disease (PKD), but data from clinical trials are lacking. METHODS: Ten autosomal dominant PKD (ADPKD) patients with rapid disease progression were enrolled at visit V1 and initially maintained a carbohydrate-rich diet. At V2, patients entered one of the two KDI arms: a 3-day water fast (WF) or a 14-day ketogenic diet (KD). At V3, they resumed their normal diet for 3-6 weeks until V4. At each visit, magnetic resonance imaging kidney and liver volumetry was performed. Ketone bodies were evaluated to assess metabolic efficacy and questionnaires were used to determine feasibility. RESULTS: All participants [KD n = 5, WF n = 5; age 39.8 ± 11.6 years; estimated glomerular filtration rate 82 ± 23.5 mL/min/1.73 m2; total kidney volume (TKV) 2224 ± 1156 mL] were classified as Mayo Class 1C-1E. Acetone levels in breath and beta-hydroxybutyrate (BHB) blood levels increased in both study arms (V1 to V2 average acetone: 2.7 ± 1.2 p.p.m., V2 to V3: 22.8 ± 11.9 p.p.m., P = .0006; V1 to V2 average BHB: 0.22 ± 0.08 mmol/L, V2 to V3: 1.88 ± 0.93 mmol/L, P = .0008). Nine of 10 patients reached a ketogenic state and 9/10 evaluated KDIs as feasible. TKV did not change during this trial. However, we found a significant impact on total liver volume (ΔTLV V2 to V3: -7.7%, P = .01), mediated by changes in its non-cystic fraction. CONCLUSIONS: RESET-PKD demonstrates that short-term KDIs potently induce ketogenesis and are feasible for ADPKD patients in daily life. While TLV quickly changed upon the onset of ketogenesis, changes in TKV may require longer-term interventions.
引用
- Oehm S, Steinke K, Schmidt J, et al. RESET-PKD: a pilot trial on short-term ketogenic interventions in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2023. PMID: 36423335. doi:10.1093/ndt/gfac311
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。